July 2020- Volume 16, Issue 7

In this Issue

Business & Government Policy

Q&A: Branching out with RNA-targeting Cas systems

Q&A: Branching out with RNA-targeting Cas systems

DDN speaks with two senior executives at Locarna to find out more about RNA-targeting Cas systems and how they work

Patent Docs: U.S. Trade Representative Releases 2020 Special 301 Report

Patent Docs: U.S. Trade Representative Releases 2020 Special 301 Report

Once again this year, the report highlights compulsory licensing as a particular concern with regard to pharmaceuticals and medical devices

NMPA approves Optune for glioblastoma

NMPA approves Optune for glioblastoma

Adding Optune to chemotherapy more than doubled five-year overall survival rate

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Foresight and Van Heron form strategic alliance

Foresight and Van Heron form strategic alliance

Partnership aims to improve drug and enzyme discovery, bioremediation, cell culture work and more

Research & Development

DDN Webinar: A CRISPR Focus on Editing

DDN Webinar: A CRISPR Focus on Editing

DDN Webinar: A CRISPR Focus on Editing

Recent advances push the gene-editing platform from analytic resource to therapeutic solution.

A closer look at splicing

A closer look at splicing

Roswell Park study finds aggressive prostate cancer marked by abnormal RNA splicing
Webinar: Synthetic DNA Technologies Enable Fast and Responsive Antibody-based Therapeutics and Diagnostics for SARS-CoV-2

Webinar: Synthetic DNA Technologies Enable Fast and Responsive Antibody-based Therapeutics and Diagnostics for SARS-CoV-2

Webinar: Synthetic DNA Technologies Enable Fast and Responsive Antibody-based Therapeutics and Diagnostics for SARS-CoV-2

Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions for the biotechnology industry.
Repurposing in a crisis: Tackling the COVID-19 wildfire

Repurposing in a crisis: Tackling the COVID-19 wildfire

Repurposing in a crisis: Tackling the COVID-19 wildfire

While the race for a vaccine targeting the SARS-CoV-2 coronavirus is expected to take another year or so, there is an increasingly urgent need to fight the disease in those already infected.

Clinical Trials

Mixed results

Mixed results

MD Anderson touts candidate for lung and ovarian cancer, but breast therapeutic falls short

Accelerating clinical trials

Accelerating clinical trials

Royal Philips initiative will run patient-centric clinical trials, reaching those who are sheltered at home

BRIDGE-ing the gap in Fabry disease

BRIDGE-ing the gap in Fabry disease

Protalix’s pegunigalsidase alfa posts strong results in Phase 3 BRIDGE trial

A boost to sorafenib?

A boost to sorafenib?

MiNA presents results from study of MTL CEBPA in combo with sorafenib in liver cancer

Mastering MS

Mastering MS

New drug could be 50 to 100 times more potent than existing options

Endogenous treatment for NASH

Endogenous treatment for NASH

Axcella reports that AXA1125 performed well in models of NASH and diabetes

Editor's Focus

Editor’s Focus: Don’t rush a vaccine

Editor’s Focus: Don’t rush a vaccine

Even with caution and care, sometimes vaccination goes awry, so we need to make sure we do it right for SARS-CoV-2 and not simply do it fast

Commentary

Out of Order: All in?

Out of Order: All in?

Representation and diversity in life-sciences research matters as much in preclinical as it does in trials

Guest Commentary: A new wave of genomic medicine

Guest Commentary: A new wave of genomic medicine

A look at work to bring us medicines that target regulatory regions of the genome to control the expression of genes

Special Reports

Feature

Focus Feature on SARS-CoV-2: Continuing the COVID fight

Focus Feature on SARS-CoV-2: Continuing the COVID fight

In this roundup of recent COVID-19 research news, we take a look at new insights into coronavirus mutation that may inform therapeutic research, discuss the idea of a global approach to a vaccine and more

Preclinical

Antibacterial activity against MRSA

Antibacterial activity against MRSA

New class of antibiotics seems to have broad-spectrum antibacterial potential

Targeting GALC in Krabbe disease

Targeting GALC in Krabbe disease

Passage Bio presents data from animal models injected with AAVhu68

Upregulating to success

Upregulating to success

Specially designed fusion protein ALKS 4230 could target many solid tumors

Diagnostics

TAPS aims for gold (standard)

TAPS aims for gold (standard)

Base Genomics raises $11M to develop and commercialize epigenetic technology for early detection of cancer

Testing for COVID-19

Testing for COVID-19

Avacta and Adeptrix collaborate on new antigen test to identify coronavirus

Signature, please

Signature, please

Gene signature found for poor response to standard chemotherapy in rare uterine cancer

SEEK and ye shall find

SEEK and ye shall find

Thrive’s blood test reportedly identifies multiple types of cancer

Discovery

When in ROME...

When in ROME...

ROME Therapeutics launches with a focus on repeatome-based drug discovery
OSE brings CLEC-1 to AACRR

OSE brings CLEC-1 to AACRR

OSE brings CLEC-1 to AACRR

CLEC-1 is a new therapeutic target for immuno-oncology. 
The research program focuses on developing a cancer immunotherapy targeting CLEC-1, a newly identified C-type lectin receptor, to block suppressive functions of myeloid cells and restore antitumor response to T lymphocytes. Suppressive myeloid cells have the ability to accumulate in the tumor microenvironment and deregulate the immune activation of T lymphocytes.
AI yields new antibiotic

AI yields new antibiotic

AI yields new antibiotic

 In their new study, the researchers also identified several other promising antibiotic candidates, which they plan to test further. They believe the model could also be used to design new drugs, based on what it has learned about chemical structures that enable drugs to kill bacteria.
IONTAS announces collaboration

IONTAS announces collaboration

IONTAS announces collaboration

Partnership with Inotrem will seek to identify novel immunotherapy targets
A Network Approach to Target Validation

A Network Approach to Target Validation

A Network Approach to Target Validation

Walter Kolch, co-founder and director of Systems Biology Ireland discusses the merits of a network approach to target validation and why probing clinical samples early is critical to increasing drug development success.

Contract Services

CROs create COVID partnership

CROs create COVID partnership

U.K companies seek to provide drug discovery and development services despite pandemic restrictions

Antibody aid

Antibody aid

CROs FairJourney Biologics and Iontas join forces to expedite identifying antibodies to fight COVID-19

The future face of clinical trials?

The future face of clinical trials?

PPD offers digital solutions amid the COVID-19 pandemic

An API boost

An API boost

Evonik announces first stage of program to increase contract manufacturing in Germany
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue's Magazine Cover

Latest Issue  

• Volume 16 • Issue 10 • November 2020

November 2020

November 2020 Issue